Cervarix is a vaccine against certain types of the human papillomavirus (HPV) that cause cervical cancer, manufacture by GlaxoSmithKline. It is designed to prevent infection from HPV types 16 and 18, which currently cause about 70% of cervical cancer cases. Type 16 has also been found to be associated with oropharyngeal squamous-cell carcinoma, a form of throat cancer. Additionally, some cross-reactive protection against virus strains 45 and 31 were shown in clinical trials. Cervarix is also formulated with AS04, a proprietary adjuvant that has been found to boost the immune system response for a longer period of time.